Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 1, 2008, Pages 97-104

  Baur, Martina ^a,b   Drescher, Anne ^c   Gneist, Margit ^a   Dittrich, Christian ^a,b   Jaehde, Ulrich ^c  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b Centre for Oncology and Hematology   (Austria)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Dose adaptation; Hepatic dysfunction; Liver dysfunction; Oxaliplatin; Pharmacokinetics

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BILIRUBIN; CAPECITABINE; CYTOTOXIC AGENT; EPIRUBICIN; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; GEMCITABINE; NAVELBINE; OXALIPLATIN; PLATINUM;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; AUTOPSY; BLOOD SAMPLING; BREAST CANCER; CANCER GROWTH; CASE REPORT; CLINICAL FEATURE; COLON CANCER; CONTROLLED STUDY; DETERIORATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG TOLERABILITY; EXTRAHEPATIC BILE DUCT OBSTRUCTION; FEMALE; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER METASTASIS; LUNG METASTASIS; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; PLEURA EFFUSION; PRIORITY JOURNAL; RADIATION DOSE; RECTUM CARCINOMA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BILIRUBIN; BREAST NEOPLASMS; COLONIC NEOPLASMS; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; LIVER; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; ORGANOPLATINUM COMPOUNDS; SPECTROPHOTOMETRY, ATOMIC;

EID: 34848830874     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0452-5     Document Type: Article

References (24)

1. Sasson AR, Sigurdson ER (2002) Surgical treatment of liver metastases. Semin Oncol 29:107-118
2. Bismuth H, Adam R, Levi F, farabos C, Waechter F, Castaing D, Majno P, Engerran L (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509-522
3. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229-237
4. Sumpter KA, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR, Ward C, Iveson T, Nicolson M, Hickish T, Hill M, Oates J (2005) Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 92:1976-1983
5. Garufi C, Nistico C, Brienza S, Vaccaro A, Dòttavio A, Zappala AR, Aschelter AM, Terzoli E (2001) Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study. Ann Oncol 12:179-182
6. Levi F, Metzger G, Massari C, Milano G (2000) Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 38:1-21
7. Massari C, Brienza S, Rotarski M, Gastiaburu J, Misset JL, Cupissol D, Alafaci E, Dutetre-Catella H, Bastian G (2000) Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol 45:157-164
8. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E (2000) Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6:1205-1218
9. Junker AM, Pieck AC, Wehmeier A, Jaehde U (2002) Interindividual differences in oxaliplatin pharmacokinetics. Int J Clin Pharmacol Ther 40:569-570
10. Eklund JW, Trifilio S, Mulcahy MF (2005) Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park) 19:1057-1063
11. Doroshow JH, Synold TW, Gandara D, Mani S, Remick SC, Mulkerin D, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Takimoto CH, Ivy P (2003) Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol 30(suppl15):14-19
12. Raymond E, Chaney SG, Taama A, Cvitkovic E (1998) Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9:1053-1071
13. Sorich J, Taubes B, Wagner A, Hochster H (2004) Oxaliplatin: practical guidelines for administration. Clin J Oncol Nursing 8:251-256
14. Kloft C, Appelius H, Siegert W, Schunack W, Jaehde U (1999) Determination of platinum complexes with antitumor activity in clinical samples by a rapid flameless atomic absorption spectrometry assay. Ther Drug Monit 21:631-637
15. US Department of Health and Human Services, FDA, CDER and CVM (2001) Guidance for industry: bioanalytical method validation
16. Shord SS, Bernard SA, Lindley C, Blodgett A, Mehta V, Churchel MA, Poole M, Pescatore SL, Luo FR, Chaney SG (2002) Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity. Anticancer Res 22: 2301-2309
17. Strickmann DB, Küng A, Keppler B (2002) Application of capillary electrophoresis-mass spectrometry for the investigation of the binding behavior of oxaliplatin to 5′-GMP in the presence of the sulfur-containing amino acid l-methionine. Electrophoresis 23:74-80
18. Kupsch P, Henning BF, Passarge K, Richly H, Wiesemann K, Hilger RA, Scheulen ME, Christensen O, Brendel E, Schwartz B, Hofstra E, Voigtmann R, Seeber S, Strumberg D (2005) Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer 5:188-196
19. Pieck AC, Drescher A, Wiesmann KG, Messerschmidt J, Weber G, Strumberg D, Hilger RA, Scheulen ME, Jaehde U (2007) Oxaliplatin-DNA adduct formation in white blood cells after administration of oxaliplatin: a potential parameter for individual dose adaptation? (submitted)
20. Bastian G, Barrail A, Urien S (2003) Population pharmacokinetics of oxaliplatin in patients with metastatic cancer. Anticancer Drugs 14:817-824
21. Ehrsson H, Wallin I, Yachnin J. (2002) Pharmacokinetics of oxaliplatin in humans. Med Oncol 19:261-265
22. Allain P, Heudi O, Cailleux A, Le Bouil A, Larra F, Boisdron-Celle M, Gamelin E (2000) Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab Dispos 28:1379-1384
23. Luo FR, Wyrick SD, Chaney SG (1999) Biotransformations of oxaliplatin in rat blood in vitro. J Biochem Mol Toxicol 13(3-4):159-169
24. Luo FR, Wyrick SD, Chaney SG (1999) Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats. Cancer Chemother Pharmacol 44:19-28